Company news
Atyr Pharma, Inc. (NASDAQ:ATYR) news
Atyr Pharma, Inc. news releases on 6ix. Latest, Apr 1, 2022: aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society…
Press releases — page 3
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
March 31, 2022
aTyr Pharma Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update
March 13, 2022
aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on Efzofitimod for the Treatment of Pulmonary Sarcoidosis
March 9, 2022
aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
March 7, 2022
aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name
January 12, 2022
aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoidosis
January 5, 2022
aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources
December 23, 2021
aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr’s Lead Therapeutic Candidate ATYR1923
November 29, 2021
aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update
November 9, 2021
aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting
November 8, 2021
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
November 2, 2021
aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs
October 5, 2021
aTyr Pharma Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting
September 30, 2021
aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 19, 2021
aTyr Pharma Announces Pricing of $75 Million Public Offering of Common Stock
September 15, 2021
aTyr Pharma Announces Proposed Public Offering of Common Stock
September 14, 2021
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
September 12, 2021
aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update
August 9, 2021
aTyr Pharma Announces Expansion of Research Collaboration with The Ohio State University
August 9, 2021
aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress
August 8, 2021
aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung
July 28, 2021
aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
July 7, 2021
aTyr Pharma Strengthens Board of Directors with Appointment of Dr. Sara Zaknoen
May 24, 2021
aTyr Pharma Presents Preclinical Research Highlighting Mechanistic Insights into Tumor Inhibitory Effects of ATYR2810
May 18, 2021
aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update
May 12, 2021
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestones for First Year of Government Grant to Develop Bispecific Antibody Platform
May 11, 2021
aTyr Pharma Announces Promotion of Leslie Nangle, Ph.D., to Vice President of Research
May 10, 2021
aTyr Pharma to Webcast Conference Call Reporting First Quarter 2021 Financial Results
May 5, 2021
aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810
April 13, 2021
aTyr Pharma Announces Co-Founder of the Foundation for Sarcoidosis Research and Leading Sarcoidosis Advocate Andrea Wilson as Patient Advisor
April 7, 2021
aTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update
March 22, 2021
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2020 Financial Results
March 15, 2021
aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications
March 14, 2021
aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting
March 10, 2021
aTyr Pharma Announces New tRNA Synthetase Discovery Programs
February 10, 2021
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan
January 13, 2021
aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
January 3, 2021
aTyr Pharma Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
December 20, 2020
aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update
November 11, 2020
aTyr Pharma Announces Publication in the Journal mAbs
November 10, 2020
aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline
November 9, 2020
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2020 Financial Results - Management to host conference call and webcast on November 12th at 5:00 pm EST / 2:00 pm PST
November 4, 2020
aTyr Pharma Announces Research Collaboration with Medical University of South Carolina
October 28, 2020
aTyr Pharma Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
October 25, 2020
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Doses First Subjects in Phase 1 Trial of ATYR1923 in Japan
September 14, 2020
aTyr Pharma Announces $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
September 13, 2020
aTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial Programs
August 12, 2020
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Proceeds to Phase 1 Trial of ATYR1923 in Japan
August 10, 2020
aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II
June 21, 2020
aTyr Pharma Announces Dosing of First Patient in Phase 2 Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
June 14, 2020